The drug treatment, LUPKYNIS® (voclosporin), reduced inflammation and prevented development of kidney damage in people with lupus nephritis (LN, lupus-related kidney disease) over 18 months. Those taking the medication also didn’t exhibit any signs of kidney-related toxicity. LUPKYINS® is a novel, structurally modified calcineurin inhibitor (CNI) that works in two ways – acting as an immunosuppressant through inhibition of T-cell activation and cytokine production, and by promoting podocyte stability in the kidney.




Article Credit: Lupus Foundation of America |